NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $11.14 -0.14 (-1.24%) (As of 11:39 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About NeuroPace Stock (NASDAQ:NPCE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeuroPace alerts:Sign Up Key Stats Today's Range$11.09▼$11.4550-Day Range$5.90▼$11.9352-Week Range$5.45▼$18.15Volume13,940 shsAverage Volume95,998 shsMarket Capitalization$332.53 millionP/E RatioN/ADividend YieldN/APrice Target$14.60Consensus RatingModerate Buy Company OverviewNeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More… With the “Bitcoin Loophole” you can help supercharge the gains by 10x or more! (Ad)You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!>> Tap here to sign up and join them for the imminent workshop NeuroPace Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks73rd Percentile Overall ScoreNPCE MarketRank™: NeuroPace scored higher than 73% of companies evaluated by MarketBeat, and ranked 302nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has only been the subject of 1 research reports in the past 90 days.Read more about NeuroPace's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 14.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.12% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in NeuroPace has recently decreased by 33.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.12% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in NeuroPace has recently decreased by 33.68%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.60 News SentimentNeuroPace has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroPace this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,916.00 in company stock.Percentage Held by Insiders22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Stock News HeadlinesLake Street Sticks to Its Buy Rating for NeuroPace (NPCE)December 6 at 2:47 AM | markets.businessinsider.comNeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual MeetingDecember 4, 2024 | globenewswire.comAffordable AI Plays: 2 Stocks Under $10 with Huge Potential!As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.December 9, 2024 | Darwin (Ad)NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut SyndromeDecember 3, 2024 | globenewswire.comStrong Buy Recommendation for NeuroPace Amid Promising RNS System Results and Anticipated Market AdvancementsNovember 22, 2024 | markets.businessinsider.comNeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy RatingNovember 15, 2024 | markets.businessinsider.comNeuroPace price target lowered to $13 from $15 at Wells FargoNovember 13, 2024 | markets.businessinsider.comNeuroPace’s Strong Financial Performance and Strategic Advancements Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comSee More Headlines NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $10.31 at the beginning of the year. Since then, NPCE stock has increased by 9.7% and is now trading at $11.31. View the best growth stocks for 2024 here. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analysts' expectations of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative trailing twelve-month return on equity of 205.41%. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's top institutional shareholders include Geode Capital Management LLC (1.09%), State Street Corp (0.53%), Barclays PLC (0.07%) and Barclays PLC (0.07%). Insiders that own company stock include Ltd Kck, Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Irina Ridley. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeuroPace own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings11/12/2024Today12/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$14.60 High Stock Price Target$22.00 Low Stock Price Target$8.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-36.74% Pretax Margin-36.74% Return on Equity-205.41% Return on Assets-28.29% Debt Debt-to-Equity Ratio6.03 Current Ratio5.59 Quick Ratio4.77 Sales & Book Value Annual Sales$65.42 million Price / Sales5.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book14.32Miscellaneous Outstanding Shares29,850,000Free Float23,222,000Market Cap$337.60 million OptionableOptionable Beta2.05 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NPCE) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.